| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Compound of black pepper that boosts bioavailability of curcumin piperine’s bioenhancing function, often more important than piperine’s direct anticancer activity Mechanisms of bioenhancement | Mechanism | Effect | | ----------------------------- | ---------------------------------- | | **↓ CYP3A4, CYP2C9** | Slows metabolic clearance | | **↓ UGT (glucuronidation)** | Increases parent compound exposure | | **↓ P-glycoprotein (ABCB1)** | Improves intracellular retention | | **↑ Intestinal permeability** | Better oral absorption | -Curcumin: ↑ bioavailability ~20–30× -Resveratrol, EGCG, quercetin: ↑ exposure 2–10× Primary pathways: NF-κB, STAT3, PI3K/Akt/mTOR, apoptosis, EMT Direct anticancer potency: modest Bioenhancing value: central and often dominant
|
| Source: |
| Type: |
| Also known as Cadherin2 (CDH2). N-cadherin is a type of cell adhesion molecule that plays a crucial role in the development and maintenance of tissue structure. In the context of cancer, N-cadherin has been implicated in the progression and metastasis of various types of tumors. N-cadherin expression is increased in various types of cancer. Normally, N-cadherin is expressed in mesenchymal cells, such as fibroblasts and smooth muscle cells. However, in cancer cells, N-cadherin expression is often upregulated, which can contribute to the epithelial-to-mesenchymal transition (EMT). EMT is a process by which epithelial cells acquire a more mesenchymal phenotype, which is characterized by increased motility, invasiveness, and resistance to apoptosis. The expression of N-cadherin in cancer cells is closely associated with tumorigenesis and metastasis. Additionally, the soluble N-cadherin level in the serum of cancer patients is much higher than that in the serum of healthy patients, revealing a positive relation with poor prognosis. |
| 1131- | PI, | Piperlongumine‑loaded nanoparticles inhibit the growth, migration and invasion and epithelial‑to‑mesenchymal transition of triple‑negative breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:133 Target#:355 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid